LT2552920T - Nauji nk-3 receptoriaus selektyvūs antagonistų junginiai, farmacinė kompozicija ir būdai, skirti naudoti nk-3 receptoriaus sąlygotų sutrikimų gydymui - Google Patents

Nauji nk-3 receptoriaus selektyvūs antagonistų junginiai, farmacinė kompozicija ir būdai, skirti naudoti nk-3 receptoriaus sąlygotų sutrikimų gydymui

Info

Publication number
LT2552920T
LT2552920T LTEP11711922.2T LT11711922T LT2552920T LT 2552920 T LT2552920 T LT 2552920T LT 11711922 T LT11711922 T LT 11711922T LT 2552920 T LT2552920 T LT 2552920T
Authority
LT
Lithuania
Prior art keywords
novel
methods
pharmaceutical composition
mediated disorders
antagonist compounds
Prior art date
Application number
LTEP11711922.2T
Other languages
English (en)
Inventor
Hamid Hoveyda
Marie-Odile Roy
Graeme Lovat Fraser
Guillaume Dutheuil
Original Assignee
Ogeda Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ogeda Sa filed Critical Ogeda Sa
Publication of LT2552920T publication Critical patent/LT2552920T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Theoretical Computer Science (AREA)
  • Databases & Information Systems (AREA)
LTEP11711922.2T 2010-04-02 2011-04-04 Nauji nk-3 receptoriaus selektyvūs antagonistų junginiai, farmacinė kompozicija ir būdai, skirti naudoti nk-3 receptoriaus sąlygotų sutrikimų gydymui LT2552920T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305343 2010-04-02
US37902810P 2010-09-01 2010-09-01
PCT/EP2011/055218 WO2011121137A1 (en) 2010-04-02 2011-04-04 Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders

Publications (1)

Publication Number Publication Date
LT2552920T true LT2552920T (lt) 2017-06-12

Family

ID=42314283

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11711922.2T LT2552920T (lt) 2010-04-02 2011-04-04 Nauji nk-3 receptoriaus selektyvūs antagonistų junginiai, farmacinė kompozicija ir būdai, skirti naudoti nk-3 receptoriaus sąlygotų sutrikimų gydymui

Country Status (21)

Country Link
US (4) US8871761B2 (lt)
EP (2) EP2552920B1 (lt)
JP (1) JP5822911B2 (lt)
KR (1) KR101878888B1 (lt)
CN (1) CN102906093B (lt)
AU (1) AU2011234398B8 (lt)
BR (1) BR112012025101B1 (lt)
CA (1) CA2793313C (lt)
DK (1) DK2552920T3 (lt)
EA (1) EA023161B1 (lt)
ES (1) ES2627688T3 (lt)
HR (1) HRP20170712T1 (lt)
HU (1) HUE032770T2 (lt)
LT (1) LT2552920T (lt)
MX (1) MX342161B (lt)
PL (1) PL2552920T3 (lt)
PT (1) PT2552920T (lt)
RS (1) RS55997B1 (lt)
SI (1) SI2552920T1 (lt)
SM (1) SMT201700282T1 (lt)
WO (1) WO2011121137A1 (lt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2695903B2 (ja) 1989-03-10 1998-01-14 沖電気工業株式会社 音声パケット欠落補償波形の歪量算出方式
US8501946B2 (en) * 2009-04-29 2013-08-06 Glaxo Group Limited 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators
WO2011082010A1 (en) * 2009-12-29 2011-07-07 Eli Lilly And Company Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
EP2552920B1 (en) 2010-04-02 2017-03-15 Ogeda Sa Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
HUE028858T2 (hu) 2011-10-03 2017-01-30 Euroscreen Sa Új királis N-acil-5,6,7,(8-szubsztituált)-tetrahidro-[1,2,4]triazolo[4,3-A]pirazinok mint szelektív NK-3 receptor antagonisták, gyógyászati készítmény és eljárások NK-3 receptor által közvetített rendellenességek során történõ alkalmazásra
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
EP2970271B1 (en) 2013-03-14 2017-11-08 Janssen Pharmaceutica NV P2x7 modulators
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
CA2907814C (en) * 2013-03-29 2021-07-13 Euroscreen Sa Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
AU2014242907B2 (en) * 2013-03-29 2018-06-28 Ogeda Sa Novel N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
US10183948B2 (en) 2013-03-29 2019-01-22 Ogeda Sa N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
NO2948455T3 (lt) * 2013-03-29 2018-02-24
WO2014170648A1 (en) * 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
GB201315846D0 (en) 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
NZ723203A (en) 2014-02-13 2020-08-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
JP6625616B2 (ja) * 2014-09-12 2019-12-25 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節ｎ−アシル−トリアゾロピラジン
ES2711095T3 (es) * 2014-09-25 2019-04-30 Ogeda Sa Nueva síntesis quiral de N-acil-(3-sustituida)-(8-sustituida)-5,6-dihidro-[1,2,4]triazolo [4,3-a] pirazinas
SMT202300471T1 (it) * 2015-03-16 2024-03-13 Ogeda N V Antagonisti del recettore nk-3 per il trattamento terapeutico o cosmetico del grasso corporeo in eccesso
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
JP7427363B2 (ja) 2015-08-12 2024-02-05 インサイト・ホールディングス・コーポレイション Ｌｓｄ１阻害剤の塩
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
EP3458063A4 (en) 2016-05-18 2020-02-26 Merck Sharp & Dohme Corp. METHOD FOR USE OF TRIAZOLO-PYRAZINYL-SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISEASES
JP2021014404A (ja) * 2017-10-13 2021-02-12 アステラス製薬株式会社 トリアゾロピラジン誘導体の塩及び結晶
PH12020500600B1 (en) * 2018-01-26 2023-12-06 Recordati Ind Chimica E Farmaceutica S P A Triazole, imidazole and pyrrole condensed piperazine derivatives and their use as modulators of mglu5 receptors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
TW202035409A (zh) 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
CA3123757A1 (en) 2018-12-21 2020-06-25 Ogeda Sa Synthesis of 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or of the methyl-d3 deuterated form thereof
WO2020211798A1 (zh) * 2019-04-16 2020-10-22 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
AU2020358948A1 (en) 2019-09-30 2022-05-26 Janssen Pharmaceutica Nv Radiolabelled MGL PET ligands
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
CN113527307B (zh) * 2020-04-20 2024-10-11 上海翰森生物医药科技有限公司 含三唑基的并环类衍生物抑制剂、其制备方法和应用
CN113549074A (zh) * 2020-04-26 2021-10-26 上海翰森生物医药科技有限公司 含三唑基的并环类衍生物抑制剂、其制备方法和应用
KR20230044443A (ko) * 2020-07-30 2023-04-04 상하이 한서 바이오메디컬 컴퍼니 리미티드 질소-함유 융합된 고리 유도체 억제제, 이의 제조 방법 및 이의 용도
KR102910851B1 (ko) * 2021-04-21 2026-01-09 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 이미다졸 함유 축합고리계 유도체, 이의 제조방법 및 이의 의약적 용도
EP4574826A4 (en) * 2022-10-19 2025-12-10 Changchun Genescience Pharmaceutical Co Ltd CRYSTALLINE FORM OF AN NK3R ANTAGONIST, ITS PREPARATION PROCESS AND ITS USE
TW202423413A (zh) * 2022-10-21 2024-06-16 大陸商長春金賽藥業有限責任公司 吲哚啉螺環類化合物的溶劑化物及其晶型、製備方法和用途
CN119968381A (zh) * 2022-10-21 2025-05-09 长春金赛药业有限责任公司 吲哚啉螺环类化合物的晶型、无定形物及二者的制备方法和应用
CN120787232A (zh) * 2023-03-10 2025-10-14 山东绿叶制药有限公司 Nk-3受体拮抗剂化合物、药物组合物、其制备方法和应用
EP4628491A1 (en) 2024-04-05 2025-10-08 Química Sintética, S.A. Synthesis of intermediates for the preparation of neurokinin-3 receptor antagonists
ES3054067A1 (es) 2024-07-11 2026-01-29 Moehs Iberica Sl Procedimiento de preparación de fezolinetant
CN121108124A (zh) 2024-07-11 2025-12-12 深圳市华先医药科技有限公司 一种构建非唑奈坦手性片段的路线及其中间体和制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1004609A (en) 1911-02-07 1911-10-03 Farbenfab Vorm Bayer F & Co Triphenylmethane dye.
JP3252483B2 (ja) 1992-10-20 2002-02-04 東レ株式会社 ３環性トリアゾロ誘導体の製造方法
DE60018707T2 (de) 1999-01-25 2006-02-09 Smithkline Beecham Corp. Anti-androgene und verfahren zur behandlung von krankheiten
CA2366858A1 (en) 1999-04-01 2000-10-12 Margaret Yuhua Chu-Moyer Sorbitol dehydrogenase inhibitors
EP1490335B1 (en) 2002-03-25 2007-09-19 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2494636A1 (en) 2002-08-07 2004-02-19 Novartis Ag Organic compounds as agents for the treatment of aldosterone mediated conditions
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
AR043443A1 (es) 2003-03-07 2005-07-27 Merck & Co Inc Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios
US7468437B2 (en) 2003-09-30 2008-12-23 Merck & Co., Inc. Phenyl pyrrolidine ether tachykinin receptor antagonists
US20070185095A1 (en) 2004-02-18 2007-08-09 Astrazeneca Ab Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
GB0509405D0 (en) * 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
BRPI0812504B8 (pt) * 2007-06-21 2021-05-25 Cara Therapeutics Inc composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
CA2702518A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh New piperazino-dihydrothienopyrimidine derivatives
WO2009072643A1 (en) 2007-12-03 2009-06-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof
CA2711782C (en) 2008-01-09 2017-01-03 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
WO2009090055A1 (en) 2008-01-17 2009-07-23 Grünenthal GmbH Substituted sulfonamide derivatives
EP2085398A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
US8501946B2 (en) * 2009-04-29 2013-08-06 Glaxo Group Limited 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US20120142672A1 (en) 2009-07-13 2012-06-07 Tatsuki Koike Heterocyclic compound and use thereof
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
EP2552920B1 (en) 2010-04-02 2017-03-15 Ogeda Sa Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
HUE028858T2 (hu) 2011-10-03 2017-01-30 Euroscreen Sa Új királis N-acil-5,6,7,(8-szubsztituált)-tetrahidro-[1,2,4]triazolo[4,3-A]pirazinok mint szelektív NK-3 receptor antagonisták, gyógyászati készítmény és eljárások NK-3 receptor által közvetített rendellenességek során történõ alkalmazásra
AU2014242907B2 (en) 2013-03-29 2018-06-28 Ogeda Sa Novel N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
CA2907814C (en) 2013-03-29 2021-07-13 Euroscreen Sa Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
NO2948455T3 (lt) 2013-03-29 2018-02-24

Also Published As

Publication number Publication date
ES2627688T3 (es) 2017-07-31
SI2552920T1 (sl) 2017-07-31
JP2013523697A (ja) 2013-06-17
KR20130021384A (ko) 2013-03-05
AU2011234398A2 (en) 2013-01-17
EA023161B1 (ru) 2016-04-29
PL2552920T3 (pl) 2017-08-31
CA2793313C (en) 2018-01-23
EP2552920B1 (en) 2017-03-15
US9926325B2 (en) 2018-03-27
BR112012025101A2 (pt) 2017-06-20
US10544150B2 (en) 2020-01-28
AU2011234398B8 (en) 2015-03-05
PT2552920T (pt) 2017-06-07
EP2552920A1 (en) 2013-02-06
HUE032770T2 (en) 2017-10-30
AU2011234398A1 (en) 2012-09-13
CA2793313A1 (en) 2011-10-06
SMT201700282T1 (it) 2017-07-18
US20140371218A1 (en) 2014-12-18
MX2012011132A (es) 2013-03-08
US20200125564A1 (en) 2020-04-23
DK2552920T3 (en) 2017-06-12
AU2011234398C1 (en) 2015-02-26
JP5822911B2 (ja) 2015-11-25
EA201290940A1 (ru) 2013-03-29
MX342161B (es) 2016-09-19
RS55997B1 (sr) 2017-09-29
CN102906093B (zh) 2016-01-13
AU2011234398A8 (en) 2015-03-05
WO2011121137A1 (en) 2011-10-06
KR101878888B1 (ko) 2018-08-17
BR112012025101B1 (pt) 2021-08-31
EP3176171A1 (en) 2017-06-07
HRP20170712T1 (hr) 2017-07-28
AU2011234398B2 (en) 2014-10-23
US20130023530A1 (en) 2013-01-24
US20180194772A1 (en) 2018-07-12
CN102906093A (zh) 2013-01-30
US8871761B2 (en) 2014-10-28

Similar Documents

Publication Publication Date Title
SMT201700282T1 (it) Nuovi composti antagonisti selettivi del recetiore nk-3, composizione farmaceutica e metodi per l'uso in disturbi mediati dai recettori nk-3
HUS2300037I1 (hu) Piperidinon karboxamid azaindan CGRP receptor antagonisták
PL2259774T3 (pl) Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
IL225550A0 (en) 4cxcr receptor antagonists
ZA201105323B (en) Agonists and antagonists of the sip5 receptor,and methods of uses thereof
PL2619212T3 (pl) Analogi buprenorfiny działające agonistycznie i/lub antagonistycznie na receptory opioidowe
IL221620A (en) Antagonist antibodies against the interleukin receptor 7 and methods for their use
SMT201600164B (it) Nuove n-acil-5, 6, 7, ( 8-s0stituito )-tetraidro-[1, 2, 4]triazolo[4, 3-a]pirazine chirali come antagonisti selettivi del recettore nk-3, composizione farmaceutica, e metodi per l'uso in disturbi mediati dal recettore nk-3
IL214572A (en) Annals of 9 - Alkylaryl - 9h - Furin - 6 - Converted Illamine, a Pharmaceutical Composition Containing Them and These Compounds That Are a Toll-like Colton Antagonist for the Treatment of Disease
AP3170A (en) New CCR2 receptor antagonists and uses thereof
SI2709631T1 (sl) Antagonisti receptorja cb1
IL218823A0 (en) Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
ZA201305576B (en) Trpm8 receptor antagonists
EP2617717A4 (en) ANTAGONIST OF P2X4 RECEIVER
EP2657225A4 (en) SUBSTITUTED METHYL AMINES, 5-HT6 SEROTONIN RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING
AU2011345414A1 (en) Substituted methyl amines, serotonin 5-HT6 receptor antagonists, methods for the production and use thereof
IL241743A0 (en) Non-competitive nicotinic receptor antagonists
IL212170A (en) Mineral corticoid receptor antagonists, their atrophy isomers, their medicinal preparations and their use
AP2803A (en) Pharmaceutical composition based on kinin B2 receptor antagonists and corticosteroids, and their use
ZA201105801B (en) Pharmaceutical composition containing leukotriene receptor antagonist and method for the preparation thereof
IL230334A0 (en) Non-competitive nicotinic receptor antagonists